Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2008-10-09
2010-12-28
Sitton, Jehanne S (Department: 1634)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S091200, C536S023100, C536S024300
Reexamination Certificate
active
07858317
ABSTRACT:
The invention is directed to a method of diagnosing a cell proliferative disorder of breast tissue by determining the methylation status of nucleic acids obtained from a subject. Aberrant methylation of several genes including TWIST, HOXA5, NES-1, retinoic acid receptor beta (RARβ), estrogen receptor (ER), cyclin D2, WT-1, 14.3.3 sigma, HIN-1, RASSF1A, and combinations of such genes serve as markers of breast malignancy.
REFERENCES:
patent: 5786146 (1998-07-01), Herman et al.
patent: 6017704 (2000-01-01), Herman et al.
patent: 6200756 (2001-03-01), Herman et al.
Baylin & Herman, “DNA hypermethylation in tumorigenesis: epigenetics joins genetics”,Trends in Genetics: TIG, 16(4):168-174 (2000).
Buller et al., “Validation of a multiplex methylation-sensitive PCR assay for the diagnosis of Prader-Willi and Angelman's syndromes”,Mol. Diagn., 5(3):239-243 (2000).
Eads et al., “MethylLight: a high-throughput assay to measure DNA methylation”,Nucleic Acids Res., 28(e28):i-viii (2000).
Esteller et al., “Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia”,Cancer Research, 58(20):4515-4518 (1998).
Evron et al., “Detection of Brest Cancer Cells in Ductal Lavage Fluid by Methylation-specific PCR”,The Lancet, 357:1335-1336 (2001).
Ferguson et al., “High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer”,Proc. Natl. Acad. Sci. U S A., 97(11):6049-6054 (2000).
Ferguson et al., “Demethylation of the Estrogen Receptor Gene in Estrogen Receptor-negative Breast Cancer Cells Can Reactivate Estrogen Receptor Gene Expression”,Cancer Research, 55:2279-2283 (1995).
Goessl et al., “Fluorescent Methylation-specific Polymerase Chain Reaction for DNA-based Detection of Prostate Cancer in Bodily Fluids”,Cancer Res., 60:5941-5945 (2000).
Herman et al., “Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands”,Proc. Natl. Acad. Sci. U S A., 93(18):9821-9826 (1996).
Krop et al., “HIN-1, a putative cytokine highly expressed in normal but not cancerous mammary epithelial cells”,Proc. Natl. Acad. Sci. U S A., 98:9796-9801 (2001).
Lehmann et al., “Quantitative assessment of promoter hypermethylation during breast cancer development”,American Journal of Pathology, 160(2):605-612 (2002).
Nass et al., “Aberrant Methylation of the Estrogen Receptor and E-Cadherin 5′ CpG Islands Increases with Malignant Progression in Human Breast Cancer”,Cancer Research, 60:4346-4348 (2000).
Olek et al., GenBank Acession No. AX344838 (2002).
Ottaviano et al., “Methylation of the Estrogen Receptor Gene CpG Island Marks Loss of Estrogen Receptor Expression in Human Breast Cancer Cell”,Cancer Research, 54:2552-2555 (1994).
Palmisano et al., “Predicting Lung Cancer by Detecting Aberrant Promoter Methylation in Sputum”,Cancer Res., 60:5954-5958 (2000).
Pao et al., “The endothelin receptor B (EDNRB) promoter displays heterogeneous, site specific methylation patterns in normal and tumor cells”,Human Molecular Genetics, 10(9):903-910 (2001).
Raman et al., “Compromised HOXA5 function can limit p53 expression in human breast tumours”,Nature, 405:974-976 (2000).
Raman et al., “HOXA5 Regulates Expression of the Progesterone Receptor”,The Journal of Biological Chemistry, 275(34):26551-2655 (2000).
Shigematsu et al., “Aberrant methylation of HIN-1 (high in normal-1) is a frequent event in many human malignancies”,Int. J. Cancer, 113(4):600-604 (2005).
Sirchia et al., “Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor beta2 promoter in breast cancer cells”,Oncogene, 19(12):1556-1563 (2000).
Tisserand et al., “Lack of HIN-1 methylation defines specific breast tumor subtypes including medullary carcinoma of the breast and BRCA1-linked tumors”,Cancer Biology and Therapy, 2(5):559-563 (2003).
Toyota et al., “Inactivation of CACNA1G, a T-type calcium channel gene, by aberrant methylation of its 5′ CpG island in human tumors”,Cancer Research, 59(18):4535-4541 (1999).
Davidson Nancy
Dooley William C.
Evron Ella
Fackler Mary Jo
Sacchi Nicoletta
DLA Piper (LLP) US
Johns Hopkins University School of Medicine
Sitton Jehanne S
LandOfFree
Aberrantly methylated genes as markers of breast malignancy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aberrantly methylated genes as markers of breast malignancy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aberrantly methylated genes as markers of breast malignancy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4200847